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Background/aim: The aim of the study was to investigate the effect of systemic sclerosis (SSc) on quality of life and sexual function in
female patients.
Materials and methods: The study included 30 sexually active female patients with SSc and 30 healthy control subjects. For all
participants in both the patient and control groups, the female sexual index and SF-36 forms were completed and a detailed medical
and sexual history was taken.
Results: The mean age was 45.03 ± 9.22 years in the SSc group and 44.6 ± 11.52 years in the control group (P = 0.87). The SF-36 scores
in the patient group were significantly lower than those in the control group. Sexual dysfunction was found in 26/30 (86.6%) of the SSc
patients and in 6/30 (20%) of the control group (P = 0.0001). Significant differences were determined between the groups with respect
to sexual desire, arousal, lubrication, orgasm, sexual satisfaction, and pain. There was no significant relationship between the subgroups
of SSc patients, duration of disease, lung involvement, and FSFI scores.
Conclusion: Sexual dysfunction and lower health quality are common problems in female patients with systemic sclerosis.
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1. Introduction
SSc is a chronic multisystemic disease, characterized
by thickened skin due to a clinical accumulation of
connective tissue and involvement of organs such as the
lungs, gastrointestinal system (GIS), heart, and kidneys
(1). The prevalence and incidence show various differences
according to ethnic and geographical factors. The disease is
most frequently seen at ages between 30 and 50 years and
the female/male ratio is 8/1 (1).
The pathogenesis of the disease comprises a triad of
vasculopathy, activation of the immune system, and fibrosis.
Although the precise etiology is still unknown, genetic
susceptibility, environmental factors, microchimerism, and
infections may be triggering factors (2–4).
The complications of SSc have adverse effects on
quality of life and sexual function. Erectile dysfunction
(ED) prevalence in men with SSc has been reported to be
approximately 12%–81% (5,6). Although the exact causes of
ED in SSc have not been well identified, vascular, fibrotic,
and neuropathic/disautonomic factors are currently
thought to be responsible (7–9). Recent studies have shown
* Correspondence: md.ismailucar@gmail.com
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an association between ED and penile blood pressure and
penile temperature (10,11). Physical changes due to SSc
can also have an unfavorable impact on sexual function
in women. It has been reported that vaginal stenosis, joint
contractures, muscle weakness, changes in breast skin,
and joint pain lead to diminished libido, decreased vaginal
lubrication, and satisfaction (12,13). Decreased vaginal
lubrication occurs due to changes in the vaginal mucosa.
These symptoms restrict sexual activity in SSc patients
and their partners, as SSc patients fear and therefore avoid
the inevitable pain during coitus. In addition, changes in
the skin in these patients, especially in the face, can affect
self-confidence in women, which can also lead to sexual
dysfunction (12,13).
The exercise capacity of SSc patients is significantly
reduced. Therefore, symptoms such as dyspnea, fatigue, and
cough in these patients can also affect sexual activity in both
sexes (13,14).
In the present study, we aimed to investigate the impact
of SSc on the quality of life and sexual function in women
with SSc.
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2. Materials and methods
The study included 30 patients referred to Ankara
University, Rheumatology Division Outpatients clinic
who had been diagnosed with SSc clinically and from
laboratory tests. The same number of volunteers were taken
as a control group. All of the patients and the control group
were asked whether they were married or not and sexually
active or not before being included in the study. Informed
consent was obtained from all participants. Approval for
the study was granted by the Local Institutional Ethics
Committee.
The SF-36 quality of life (QoL) questionnaire was
administered to all study participants; to determine sexual
dysfunction, the female sexual function index (FSFI) was
applied to both groups. The Turkish version of the FSFI,
whose validity and reliability in Turkish society have been
confirmed, was used (15). All the questionnaires were
evaluated by the same investigator.
A total score under <22.7 on the FSFI was evaluated as
sexual dysfunction. A score <3.6 on the sexual desire test
was evaluated as diminished libido, of <3.9 on the arousal
test as arousal dysfunction, of <3.6 on the lubrication test
as lubrication dysfunction, of <3.6 on the orgasm test as
orgasmic dysfunction, of <3.6 in the sexual satisfaction
test as sexual dissatisfaction, and of <4 on the sexual pain
dysfunction test as sexual pain dysfunction.
Statistical analyses of the data of the patients and
control cases were performed with SPSS 15.0. Normally
distributed variables were stated as mean ± standard
deviation (SD) values, nonnormally distributed variables
as median (minimum–maximum) values, and nominal
variables as number and percentage (%). The t-test was
applied in the comparisons of mean differences and the
Mann–Whitney test in the analysis of median differences,
as there were only 2 groups. Relationships between constant
variables were evaluated with the Spearman correlation
test for nonnormally distributed variables and the Pearson
correlation test for normally distributed variables. A value
of P < 0.05 was accepted as statistically significant.
3. Results
The mean age was 45.03 ± 9.22 years (range: 30–62 years)
in the patient group and 44.6 ± 11.52 years (range: 28–64
years) in the control group. No significant difference was
determined between the groups in terms of age (P = 0.87).
In the SSc patient group, 16 patients (53.3%) were
diagnosed with diffuse cutaneous systemic sclerosis and 14
patients (46.7%) with limited cutaneous systemic sclerosis.
Lung involvement was determined in 15 patients (50%).
ANA was positive in all 30 patients, Scl-70 was positive in
14 (46.7%), anticentromere antibody was positive in 10
(33.3%) patients, SS-A was positive in 5 (16.6%), and U1RNP antibody was positive in 4 (13.3%). Table 1 presents

the data on the clinical and laboratory findings of the SSc
patients.
When the data of the submitted questionnaires were
compared, a significant difference was determined between
the 2 groups, especially in the subgroup evaluation of
physical function, the role of physical and emotional
restriction, pain, energy, social function, mental health,
and general health state. The findings of SF-36 QoL are
shown in Table 2.
When the total scores of the FSFI were established,
sexual dysfunction was found in 26/30 (86.6%) of the SSc
patients and in 6/30 (20%) of the control group. There was
a statistically significant difference between the groups
(P < 0.0001). In the FSFI subgroup evaluation, sexual
desire dysfunction was determined in 21 (70%) patients,
arousal dysfunction in 24 (80%), lubrication dysfunction
in 19 (63.3%), orgasmic dysfunction in 18 (60%), sexual
dissatisfaction in 4 (13.3%), and sexual pain dysfunction in
7 (23.3%) patients. Significant differences were determined
between the groups with respect to sexual desire, arousal,
lubrication, orgasm, sexual satisfaction, and pain (Table 3).
When the SF-36 data and FSFI data were compared,
a strong positive correlation in terms of sexual function,
physical component scale, and physical scales (role of
physical restriction, pain, and general health) was detected.
There was no significant relationship between the
subgroups of SSc patients, duration of disease, or lung
involvement and FSFI scores. Significant and strong
negative correlations were determined between age and
FSFI scores (Tables 4 and 5).
4. Discussion
The prevalence of SSc in females has been reported to be
8 times greater than that in males (16). Although the high
frequency of this disease in females is well known, there have
been few studies investigating female sexual dysfunction.
Therefore, the present study can be considered of value; it
is the first study in Turkey to have investigated this issue in

Table 1. Clinical and laboratory findings in SSc patients
The features of the SSc patient group

Patient
N = 30 (100%)

Diffuse cutaneous SSc
Limited cutaneous SSc
Lung involvement
Positive ANA
Positive anti-Scl-70
Positive anticentromere
Positive SS-A
Positive U1-RNP

16 (53.3%)
14 (46.7%)
15 (50%)
30 (100%)
14 (46.7%)
10 (33.3%)
5 (16.6%)
4 (13.3%)
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Table 2. Evaluation of SF-36 data in the SSc and control groups.
SF-36

SSc groupMean ± SD

Control group Mean ± SD

Physical function

63 ± 23.54

79.67 ± 12.8

P
0.001

The role of physical restriction

37.5 ± 40.86

85.8 ± 16

0.0001

The role of emotional restriction

38.93 ± 37.3

75.56 ± 23.9

0.004

Pain

46.17 ± 29.2

68.73 ± 17.12

0.001

Energy

35.83 ± 16.2

51.33 ± 18.2

0.001

Social function

50.8 ± 26.9

65 ± 26.13

0.03

Mental health

60.27 ± 14.1

76.8 ± 13.55

0.0001

General health

41.43 ± 15.77

69.67 ± 14.68

0.0001

Physical component scale

37.73 ± 10.85

48.37 ± 6.18

0.0001

Mental component scale

38.9 ± 6.4

47.2 ± 8.71

0.0001

Table 3. Comparison of the data of the SSc and control groups in the FSFI and subgroup analyses.
Sexual function index

SSc group mean ± SD

Control group mean ± SD

P

Sexual desire

2.46 ± 1.16

3.56 ± 1.37

0.002

Arousal

2.46 ± 1.59

4.05 ± 1.56

0.0001

Lubrication

2.56 ± 1.52

4.38 ± 1.54

0.0001

Orgasm

2.56 ± 1.56

4.41 ± 1.5

0.0001

Sexual satisfaction

2.5 ± 1.4

4.56 ± 1.31

0.0001

Sexual pain

2.63 ± 1.56

4.7 ± 1.61

0.0001

Total score

15.27 ± 7.2

25.63 ± 7.86

0.0001

Table 4. The evaluation of the impact of SSc subgroups on FSFI scores.

Sexual dysfunction index

dcSSc (mean ± SD)
n = 16

lcSSc (mean ± SD)
n = 14

P

Sexual desire

2.43 ± 1.2

2.5 ± 1.16

0.88

Arousal

2.37 ± 1.78

2.57 ± 1.39

0.82

Lubrication

2.25 ± 1.61

2.92 ± 1.38

0.29

Orgasm

2.31 ± 1.74

2.85 ± 1.35

0.52

Sexual satisfaction

2.12 ± 1.31

2.92 ± 1.43

0.15

Sexual pain

2.81 ± 1.83

2.42 ± 1.22

0.33

Total score

14.31 ± 7.96

16.36 ± 6.31

0.6

this patient group. When the total scores of the FSFI were
calculated, sexual dysfunction was found in 26/30 (86.6%)
of the SSc patients and in 6/30 (20%) of the control group.
There was a statistically significant difference between the
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groups (P < 0.0001). In the FSFI subgroup evaluation,
there was sexual desire dysfunction in 21 (70%) patients,
arousal dysfunction in 24 (80%), lubrication dysfunction
in 19 (63.3%), orgasmic dysfunction in 18 (60%), sexual
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Table 5. The relationship between lung involvement and the SSc and FSFI scores.
Sexual dysfunction index

Lung involvement (+)
n = 15

Lung involvement (–)
n = 15

P

Sexual desire

2.53 ± 1.18

2.4 ± 1.18

0.77

Arousal

2.53 ± 1.72

2.4 ± 1.5

0.80

Lubrication

2.4 ± 1.55

2.73 ± 1.53

0.59

Orgasm

2.46 ± 1.68

2.66 ± 1.49

0.9

Sexual satisfaction

2.2 ± 1.32

2.8 ± 1.47

0.32

Sexual pain

3 ± 1.73

2.26 ± 1.33

0.13

Total score

15.13 ± 7.5

15.4 ± 7.12

1

dissatisfaction in 4 (13.3%), and sexual pain dysfunction
in 7 (23.3%) patients. Thus, significant differences were
determined between the groups with regard to sexual
desire, arousal, lubrication, orgasm, sexual satisfaction,
and pain.
Impens et al. investigated the impact of SSc on
sexual dysfunction in 60 SSc patients; the mean FSFI
score was 24.9, which was significantly different than
that of the normal population. In the analysis of the
relationship between the SF-36 mental component scale
and the FSFI score, a strong and positive correlation
was determined (17). In the present study, a strong and
positive relationship was determined between the SF-36
physical component scale and FSFI findings. Furthermore,
statistical significance was determined between age,
subtype of disease, lung involvement, and sexual function,
comparable to the results of the Impens study.
Schouffoer et al. also investigated sexual function in 37
SSc patients in comparison with a control group. The SF36 and FSFI were administered along with a questionnaire
including features of the disease such as daily activity,
Reynaud’s phenomenon, digital ulcers, intestinal and
pulmonary symptoms, and 20 questions to determine the
pain level. The FSFI total mean score was 20.9 ± 9.4. A
significant difference was determined between the groups
with respect to the FSFI total score and subgroup score.
Moreover, a negative correlation was determined between
sexual dissatisfaction, disease duration, and FSFI total

score. No relationship was found between the FSFI score
and disease subtype (18).
Levis et al. investigated sexual dysfunction and related
clinical symptoms in an evaluation of both sexually active
and inactive patients; the causes of sexual dysfunction in
sexually inactive patients were questioned. The FSFI was
applied to 165 sexually active SSc patients. The presence of
Reynaud’s phenomenon and digital ulcers and evaluation
of the modified Rodnan skin score, GIS and pulmonary
symptoms, and pain were investigated. Sexual dysfunction
was established in 102/165 (61.8%). This dysfunction was
higher in patients of advanced age with a high Rodnan
skin score and marked pulmonary symptoms. There was
no relationship between disease duration and pulmonary
hypertension (19).
There are some limitations to our study. The patient
and the control groups were compared only for age. No
comparison was made in terms of other factors which can
affect sexual function, such as educational status, or other
mental or medical illnesses. Evaluations like modified
Rodnan skin score and respiratory function test, which
evaluate the disease grade affecting sexual function in
the patient group, were not used. In conclusion, although
sexual function is an important stress factor in women
with SSc, it has not been adequately addressed. There
should be greater awareness that sexual dysfunction and
QoL in SSc are common problems, and this issue should
not be ignored by physicians. With proper diagnosis and
support, the QoL of these patients can be improved.
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